Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor
cells and slow the growth of the tumor.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have
locally advanced or metastatic stomach cancer or cancer of the gastroesophageal junction.